

Drugs and Disease

Symposium organized by
The Royal College of Pathologists
delivered in London in February 1975

Edited by
SHEILA WORLLEDGE

Published for The Royal College of Pathologists by the
Journal of Clinical Pathology, BMA House, Tavistock Square
London WC1H 9JR England

£3.00

W4
1982.0
1985
C.2

COPYRIGHT © 1975 by
The Royal College of Pathologists

*The Journal of Clinical Pathology is published monthly
by the British Medical Association, from BMA House,
Tavistock Square, London WC1H 9JR*

Index

- Absorption, drug interactions during, 95
ADJEPON-YAMOAH, K. K. *See* PRESCOTT, L. F., FORREST, J. A. H., ADJEPON-YAMOAH, K. K., and FINLAYSON, N. D. C.
Adrenergic neurone-blockading drugs in hypertension, 36
— receptor-blockading drugs, 37
Aerosols, bronchodilator, prescribing of, survey of, 11
Agranulocytosis, drug-induced, 46, 47
Amidopyrine, agranulocytosis induced by, 46, 48
Anaemia, haemolytic, drug-induced, 46, 47
Anaesthesia, mechanism of, 1
Analgesic nephropathy, 14
—, aetiology of, 18
—, and neoplasia, 20
—, clinical syndrome of, 14
—, pathogenesis of, 17
—, pathological diagnosis of, 17
—, pathology of, 14
Ancrod, 52
Anion-exchange resins in hyperlipoproteinaemia, 109, 110
Antibiotics, sale of, survey of, 12
Antibodies, drug-specific, damage to drug-coated cells by, 47
Anticoagulants, 51
—, indications for, 52
Antidiabetic drugs in relation to vascular events, evaluation of, 99
—, oral, prescribing of, survey of, 11
Antiplatelet agents, 50
Arsenic Act (1851), 119
Aspirin and renal disease, 19
Autoimmune phenomena induced by drugs, 47
Autonomic ganglion-blockading drugs in hypertension, 36
Azathioprine, toxicity of, 26, 30, 31, 32
- Bacterial infections and immunosuppressive agents, 28
BARNES, J. M.: The widespread use of pesticides, 115
Bedford 8½-year Analysis of tolbutamide in diabetes, 101
— Tolbutamide Trial in diabetes, 100
Blood cells, damage mediated by immune complexes, 46
—, drug-coated, damage by drug-specific antibodies to, 47
— disorders, drug-induced, 40
— dyscrasias, allergic, drug-induced, immunological mechanisms in, 46
—, —, —, serological methods for detection of, 48
British Pharmacopoeia, 119
Bronchodilator aerosols, prescribing of, survey of, 11
- CAMERON, J. S.: Problems with immunosuppressive agents in renal disease, 24
Cardiovascular disorders, effect of antidiabetic agents, evaluation of, 99
Central nervous system and antihypertensive drugs, 38
Cephalothin, anaemia and thrombocytopenia induced by, 47
Cholestasis associated with drugs, 73
Cholestatic hepatitis associated with drugs, 67
CLAIREAUX, A. E.: The effect of oxygen on the lung, 75
Clofibrate in hyperlipoproteinaemia, 108, 110
Clonidine in hypertension, 37
Clotting and fibrinolysis, 50
Committee on Safety of Medicines, 121
Contraceptive pill, skin reactions to, 55
Coronary heart disease and hypolipaeic drugs, 106
Coumarin compounds, 51
Cyclic nucleotides, effect on red cell shape, 41
Cyclophosphamide, toxicity of, 27, 30, 31
- Dangerous Drugs Acts, 120
DDT, 116
Diabetes, phenformin in, trials of, 102, 103
—, tolbutamide in, mortality and morbidity, 101
—, —, —, trials of, 100, 101
Dicophane, 116
Diet, lowering of serum lipids by, effect on coronary heart disease, 112
—, restriction in hyperlipoproteinaemia, 111
Dinitroorthocresol, 115
Diuretics, thiazide, in hypertension, 37
- Drugs, action, mechanisms of, 1
—, —, specific and nonspecific, 1
—, acute liver injury associated with, 66
—, adverse reactions to and interactions of, incidence of, 94
—, —, —, incidence of, 7
—, —, —, intensive monitoring of, 9
—, —, —, literature on, 8
—, —, —, registry reports of, 8
— and kidney, 14
— and liver, 62
— and lung, 75
— and skin, 54
—, as cause of death, 12
—, autoimmune phenomena induced by, 47
—, benefits and hazards, 94
—, blood disorders induced by, 40
—, —, dyscrasias induced by, immunological mechanisms in, 46
—, —, —, serological methods for detection of, 48
—, cells coated with, damage by drug-specific antibodies to, 47
—, chronic liver disease associated with, 71
—, clinical aspects of, and skin diseases, 54
—, effect on red cell membranes, and factors determining normal red cell shape, 40
—, fixed drug eruptions, 60
— in hypertension, 36
—, interactions and lethal combinations, 94
—, —, at sites of metabolism and excretion, 96
—, —, before administration, 94
—, —, during absorption, 95
—, —, in gut, 94
—, —, pharmacodynamic, 96
—, —, plasma-protein-binding, 95
—, metabolism in liver disease, 62
—, safety of, legislation on, 119
—, skin reactions to, immunological mechanisms in, 58
—, therapeutic audit of, 10
—, toxicity, molecular basis of, 1
— with direct action on vascular resistance, 37
- Epidermal necrolysis, toxic, due to drugs, 56
Erythema due to drugs, 56
Exanthematous eruptions due to drugs, 54
- Fat solubility and anaesthetics, 1
Fibrinolysis and clotting, 50
—, pharmacological enhancement of, 52
Fibrinolytic therapy, indications for, 53
FINLAYSON, N. D. C. *See* PRESCOTT, L. F., FORREST, J. A. H., ADJEPON-YAMOAH, K. K., and FINLAYSON, N. D. C.
FORREST, J. A. H. *See* PRESCOTT, L. F., FORREST, J. A. H., ADJEPON-YAMOAH, K. K., and FINLAYSON, N. D. C.
Fungal infections and immunosuppressive agents, 28
- Ganglion-blockading drugs, autonomic, in hypertension, 36
Gin Acts, 119
Gonadal damage and immunosuppressive agents, 30
Granuloma, Wegener's, immunosuppressive agents in, 25
- Haemolytic anaemia, drug-induced, 46, 47
Halothane anaesthesia, severe hepatic necrosis after, 68
Hamman-Rich syndrome, 79
Heparin, 51
Hepatic necrosis, severe, associated with drugs, 68
Hepatitis, acute, associated with drugs, 67
—, cholestatic, associated with drugs, 67
Hepatocellular disease associated with drugs, 72
HOWARD, A. N.: Hypolipaeic drugs and coronary heart disease, 106
Hydrallazine, autoimmune phenomena induced by, 47
— in hypertension, 37
Hyperlipoproteinaemia, 106
—, advisability of treatment in, 113
—, dietary restriction in, 111
—, drugs used in, 108
—, —, —, in combination for, 110
Hypersensitivity reactions mediated by T lymphocytes, 59

- Hypertension, drug treatment of, 36
 —, treatment regimes in, 38
 Hypnotic drugs, prescribing of, survey of, 10
 Hypoglycaemic drugs, oral, prescribing of, survey of, 11
 Hypolipaeic drugs and coronary heart disease, 106
 —, types and effects, 108
 — used in combination, 110
- Immune complexes, cell damage mediated by, 46
 Immunological mechanisms in drug-induced blood dyscrasias, 46
 — in skin reactions to drugs, 58
 Immunosuppressive agents in renal disease, 24
 —, unwanted effects of, 25
 Infection, facilitation of, and immunosuppressive agents, 27
 Intestine, drug interactions in, 94
- JACOB, H. S.: Effect of drugs on red cell membranes: insights into normal red cell shape, 40
- KEEN, H.: Antidiabetic agents and vascular events, 99
 KENNEDY, A.: Analgesic nephropathy, 14
 Kidney and drugs, 14
- Legislation and drug safety, 119
 Leucocyte methods for detection of drug-induced allergic blood dyscrasias, 48
 Leucopenia, drug-induced, 46, 47
 Lichen planus, drug reactions resembling, 55
 Light sensitivity due to drugs, 55
 Lipids, serum, lowering by diet in coronary disease, 112
 —, —, — by drugs in coronary disease, 111
 —, —, — role in coronary heart disease, 106
 Lipoid nephrosis, immunosuppressive agents in, 25
 Lipophiles, action, modulation of specificity in, 5
 —, toxicity, possible patterns of, 4
 Liver and drugs, 62
 — disease, chronic, associated with drugs, 71
 —, —, — drug metabolism in, 62
 —, —, — in acute disease, 63
 —, —, — in chronic disease, 64
 — injury, acute, associated with drugs, 66
 —, —, — attribution to particular drug, 68
 —, —, — chronic effects of single episodes, 71
 —, —, — criteria for drug toxicity as cause, 69
 —, —, — pigmentation associated with drugs, 73
 —, —, — tumours and tumour-like nodules associated with drugs, 73
 —, —, — vascular lesions of, associated with drugs, 73
 Lung and drugs, 75
 —, effect of oxygen, 75
 —, lesions due to oxygen in adults, 75
 —, —, — in children, 76
 —, —, — in experimental animals, 76
 —, —, — influence of temperature and pressure, 78
 —, —, — mechanism of, 78
 —, —, — types of, 78
 —, pathology in paraquat poisoning, 81
 —, —, — vasculature, histopathology in paraquat poisoning, 91
 Lupus erythematosus, systemic, drugs as precipitating factor in, 56
 —, —, — glomerulonephritis, immunosuppressive agents in, 24
 Lymphocytes, T cell-mediated hypersensitivity reactions, 59
- Marrow depression and immunosuppressive agents, 27
 Medicines Act (1968), 119, 121
 Methotrexate, hepatotoxic effects of, 72
 Methyl dopa, autoimmune phenomena induced by, 47, 48
 MIESCHER, P. A. *See* NYDEGGER, U., and MIESCHER, P. A.
 Misuse of Drugs Act, 120
 Molecular basis of drug toxicity, 1
- Neomycin in hyperlipoproteinaemia, 109
 Neoplasia and analgesic nephropathy, 20
 Nephropathy, analgesic. *See* Analgesic nephropathy
 Nephrotic syndrome, minimal-change, immunosuppressive agents in, 25
 Neurone-blockading drugs, adrenergic, 36
 Nicotinic acid in hyperlipoproteinaemia, 109
 Nucleotides, cyclic, effect on red cell shape, 41
 NYDEGGER, U., and MIESCHER, P. A.: Immunological mechanisms in drug-induced blood dyscrasias, 46
- Oestrogens in hyperlipoproteinaemia, 110
- Oncogenesis and immunosuppressive agents, 31
 Oxygen at atmospheric pressure, 75
 —, effect on lung, 75
 —, hyperbaric, 75
 —, —, — therapy, influence on paraquat poisoning, 90
 —. *See also* Lung lesions due to oxygen
 Oxyphenisatin jaundice, 72
- Paracetamol, acute liver injury due to, 66
 Paraquat, hazards of, 116
 — poisoning, destructive phase of, 81
 —, —, — influence of oxygen therapy, 90
 —, —, — lung pathology in, 81
 —, —, — mechanism of toxicity in, 90
 —, —, — proliferative phase in animals after repeated doses, 85
 —, —, —, —, — after single dose, 83
 —, —, — in man, 89
 —, —, — pulmonary vasculature in, histopathology of, 91
 —, —, — treatment of, 92
 PATON, W. D. M.: The molecular basis of drug toxicity, 1
 Penicillin, immune haemolytic anaemia induced by, 47
 Pesticides, poisoning by, incidence of, 117
 — Safety Precaution Scheme, 115
 —, —, — widespread use of, 115
 Pharmacy Act (1868), 119
 — and Poisons Act, first, 120
 Phenacetin and renal disease, 19
 Phenformin in diabetes, trials of, 102, 103
 Pigmentation of liver associated with drugs, 73
 Plasma-protein-binding drug interactions, 95
 Platelet methods for detection of drug-induced allergic blood dyscrasias, 48
 Prazosin in hypertension, 38
 PRENTICE, C. R. M.: Clotting and fibrinolysis, 50
 PRESCOTT, L. F., FORREST, J. A. H., ADJEPON-YAMOAH, K. K., and FINLAYSON, N. D. C.: Drug metabolism in liver disease, 62
 Procainamide, autoimmune phenomena induced by, 47
 Propranolol and renin secretion in hypertension, 38
 Psoriasis, drug reactions resembling, 55
- Receptor-blockading drugs, adrenergic, 37
 Red cell membranes, effect of drugs, and factors determining normal red cell shape, 40
 — methods for detection of drug-induced allergic blood dyscrasias, 48
 — shape, effect of cyclic nucleotides, 41
 —, —, — of drugs, 40
 —, —, — role of spectrin, 43
 Renal disease, immunosuppressive agents in, 24
 —, —, — transplantation, immunosuppressive agents in, 24
 Renin secretion, inhibition of, and antihypertensive drugs, 38
 Resins, anion-exchange, in hyperlipoproteinaemia, 109, 110
 Respirator lung syndrome, 75
 RICHENS, A.: Drug interactions and lethal drug combinations, 94
- Safety of Drugs Committee, 120
 SCHEUER, P. J.: Long-term effects on the liver, 71
 SCOWEN, Sir E.: Legislation and drug safety, 119
 Sedormid, thrombocytopenia induced by, 46, 48
 Serum lipids, lowering by diet in coronary disease, 112
 —, —, — by drugs in coronary disease, 111
 —, —, — role in coronary heart disease, 106
 Skin and drugs, 54
 — diseases and clinical aspects of drugs, 54
 —, —, — fixed drug eruptions in, 60
 —, —, — reactions to drugs, immunological mechanisms in, 58
 —, —, — sensitizers inducing reactions to systemic drugs, 54
 SMITH, P., and HEATH, D.: The pathology of the lung in paraquat poisoning, 81
 SNEDDON, I. B.: The clinical aspects of drugs and disease of the skin, 54
 Sodium nitroprusside in hypertension, 38
 Spectrin, role in red cell shape, 43
 Spherocytosis, hereditary, 40, 41, 44
- TALBOT, I. C.: Acute liver injury, 66
 Teratogenicity and immunosuppressive agents, 31
 Thalidomide, 8
 Therapeutic Substances Act, 120
 Thiazide diuretics in hypertension, 37
 Thrombocytopenia, drug-induced, 46, 47, 48

Thrombolytic therapy, 52
D-Thyroxine in hyperlipoproteinaemia, 109
Tolbutamide in diabetes, mortality and morbidity analysis, 101
—— ———, trials of, 100, 101
Transplantation, renal, immunosuppressive agents in, 24
Tumours and tumour-like nodules of liver associated with drugs, 73
TURK, J. L.: Immunological mechanisms in the reaction between drugs
and the skin, 58

University Group Diabetes Programme, 101, 102
Urticarial reactions to drugs, 55

Vascular lesions of liver associated with drugs, 73
—— resistance, drugs acting directly on, 37
Veterinary Products Committee, 121
Viral infections and immunosuppressive agents, 28

WADE, O. L.: The incidence of adverse reactions to drugs, 7
Wegener's granuloma, immunosuppressive agents in, 25
Whitehall Phenformin Trial in diabetes, 103

YAMOAH, K. K. ADJEPON-. *See* ADJEPON-YAMOAH, K. K.
Yeast infections and immunosuppressive agents, 28

